President and CEO Sean Bohen said the company believes the emerging oral selective estrogen receptor degrader (SERD) class has proven its value over the past year, even as many earlier candidates fell ...

CEO Sean Bohen outlined the company’s focus on advancing endocrine therapies for ER-positive, HER2-negative breast cancer ...

Palazestrant (OP-1250) in combination with the CDK 4/6 inhibitors, ribociclib and palbociclib, demonstrated no significant drug-drug interaction, no dose-limiting toxicities and a tolerability profile ...

SAN FRANCISCO, March 06, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (OLMA) (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, ...

Olema Pharmaceuticals announced updated clinical results from the ongoing Phase 1b/2 study of palazestrant in combination with CDK4/6 inhibitor, ribociclib, in patients with estrogen receptor-positive ...

SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, ...

Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups Median PFS was 15.5 months in the 120 mg palazestrant cohort across all patients In ...

Olema Pharmaceuticals (OLMA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam Slutsky from LifeSci Capital maintained the rating on the stock ...

Olema Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing therapies for metastatic breast cancer, is set to report fourth-quarter results on Monday, March 2, during market ...

Exploring depression risk among breast cancer survivors: A nationwide cohort study in South Korea. An exploratory investigator-initiated trial via intrathecal or intracerebroventricular delivery of ...